Pharmafile Logo
Pharmafocus logo
Advanced Search

Votubia

Showing 5 posts of 5 posts found.

Novartis

Novartis’ brain tumour drug Votubia launched in UK

September 29, 2011
Sales and Marketing Afinitor, Votubia

Novartis has launched its orphan drug Votubia in the UK for patients with a rare type of brain tumour. Votubia …

News
Novartis

Everolimus approved to treat rare tumour disease

September 8, 2011
Sales and Marketing Novartis, SEGA, Votubia, everolimus

Novartis has gained EU approval for everolimus to be used to treat a rare non-cancerous tumour. Everolimus is already marketed …

News

Novartis’ Votubia reduces benign brain tumours in SEGA patients

July 11, 2011
Research and Development Novartis, SEGA, Votubia, everolimus

Novartis’ novel cancer drug Votubia has reduced the size of SEGA brain tumours in a late-stage trial. Votubia (or everolimus …

News
Novartis Afinitor (everolimus)

Afinitor stops tumour growth in advanced breast cancer

July 5, 2011
Manufacturing and Production, Research and Development Afinitor, Novartis, Votubia, advanced breast cancer

Novartis’ Afinitor has impressed in a late-stage trial by increasing survival in women with advanced breast cancer. The phase III …

News
Novartis

Regulators back Novartis’ Votubia

June 28, 2011
Sales and Marketing Novartis, Votubia, everolimus

Novartis’ drug Votubia has been recommended by regulators to treat a disease for which the only current option in Europe …

News
The Gateway to Local Adoption Series

Latest content

HonorHealth Research Institute announces first patient dosed with new stroke treatment

February 2, 2026

Accord Healthcare appoints Paul Burden as Associate Vice President and Country Head UK

February 2, 2026

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026

Rare diseases – spinal muscular atrophy

January 30, 2026

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026